# SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Canonical URL: https://biopharmsignal.com/news/SABS/sab-bio-announces-closing-of-85-million-public-offering-of-common-stock-and-pre-funded-warrants
Ticker: SABS
Company: SAB Biotherapeutics
Source: SAB Biotherapeutics
Published: 2026-03-19 20:01 EST
Original Source URL: https://ir.sab.bio
## Summary

MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the closing of an underwritten public

## Article Body
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the closing of an underwritten public
## Recent Company News
- 2026-07-07 12:00 EST — [Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes](https://biopharmsignal.com/news/SABS/breakthrough-t1d-awards-grant-to-support-prise-hatg-study-of-sab-142-in-stage-3--2892a9e2) — Source: SAB Biotherapeutics
- 2026-05-29 12:00 EST — [SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting](https://biopharmsignal.com/news/SABS/sab-bio-to-present-data-on-sab-142-at-the-american-diabetes-association-s-2026-scientific-sessions-and-focis-2026-annual-meeting) — Source: SAB Biotherapeutics
- 2026-05-12 11:30 EST — [SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/SABS/sab-bio-reports-q1-2026-financial-results-and-recent-business-highlights) — Source: SAB Biotherapeutics
- 2026-05-05 12:30 EST — [SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET](https://biopharmsignal.com/news/SABS/sab-bio-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-may-12-2026-08-30-am-et) — Source: SAB Biotherapeutics
- 2026-04-22 11:00 EST — [SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026](https://biopharmsignal.com/news/SABS/sab-bio-presents-additional-clinical-and-mechanistic-data-from-sab-142-phase-1-trial-in-adult-patients-with-established-autoimmune-type-1-diabetes-at-ids-2026) — Source: SAB Biotherapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)